In NSCLC, AAMP interacts with EGFR, enhancing its phosphorylation and activating the ERK1/2 pathway, thereby promoting proliferation and resistance to chemotherapy.10 This evidence concerns the gene MAPK3 and non-small cell lung carcinoma.